The DOI matches its Crossref record.
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
Abstract
Interethnic differences in debrisoquin and mephenytoin hydroxylation have been compared between normal white (n = 183) and Japanese (n = 100) subjects with the 8-hour urinary metabolic ratio of debrisoquin and the urinary S/R enantiomeric ratio of mephenytoin to identify extensive (EM) and poor (PM) metabolizers. In white subjects the frequency of PMs was 8.7% and 2.7% for debrisoquin and mephenytoin, respectively. In contrast, in Japanese subjects no PMs of debrisoquin were identified, while the incidence of PMs of mephenytoin was 18%. These substantial differences (P less than 0.001) in polymorphic distributions of oxidative drug metabolizing ability have implications for interethnic efficacy and toxicity of drugs and other xenobiotics that are metabolized by the involved cytochrome P-450 isozymes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., & Goldstein, J. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40694-6 · Cited by 956
Self-citationClinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
The Human Hepatic Cytochromes P450 Involved in Drug Metabolism
Wrighton, S. A., & Stevens, J. C. (1992) · Critical Reviews in Toxicology · doi:10.3109/10408449209145319 · Cited by 944
Guengerich, F. P. (1995) · Cytochrome P450 · doi:10.1007/978-1-4757-2391-5_14 · Cited by 728
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
Bertilsson, L., Dahl, M., Dalén, P., & Al‐Shurbaji, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01548.x · Cited by 579
Evolution of the P450 gene superfamily:
Gonzalez, F. J., & Nebert, D. W. (1990) · Trends in Genetics · doi:10.1016/0168-9525(90)90174-5 · Cited by 514
Molecular genetics of the P-450 superfamily
Gonzalez, F. J. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90006-n · Cited by 493
Newer antidepressants and the cytochrome P450 system
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.311 · Cited by 482
Serotonin Transporter: Gene, Genetic Disorders, and Pharmacogenetics
Murphy, D. L. (2004) · Molecular Interventions · doi:10.1124/mi.4.2.8 · Cited by 448
Bertilsson, L. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529030-00005 · Cited by 432
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Methadone—metabolism, pharmacokinetics and interactions
FERRARI, A., COCCIA, C., BERTOLINI, A., & STERNIERI, E. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.05.002 · Cited by 384
Cytochromes P450, Drugs, and Diseases
Guengerich, F. P. (2003) · Molecular Interventions · doi:10.1124/mi.3.4.194 · Cited by 378
The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects
Eichelbaum, M., & Gross, A. S. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90025-w · Cited by 368
Caraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in Humans
Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., & Ghanayem, B. I. (1994) · Biochemistry · doi:10.1021/bi00173a017 · Cited by 360
Genetic polymorphism of S-mephenytoin hydroxylation
Wilkinson, G. R., Peter Guengerich, F., & Branch, R. A. (1989) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(89)90047-8 · Cited by 292
Self-citationPharmacokinetics of Haloperidol
Froemming, J. S., Lam, Y. W. F., Jann, M. W., & Davis, C. M. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198917060-00004 · Cited by 291
Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population*
Kubota, T., Chiba, K., & Ishizaki, T. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90214-3 · Cited by 288
Clinical significance of the sparteine/debrisoquine oxidation polymorphism
Br�sen, K., & Gram, L. F. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00637732 · Cited by 282
Gender-related differences in pharmacokinetics and their clinical significance
Tanaka, E. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00246.x · Cited by 281
Bernard, S., Neville, K. A., Nguyen, A. T., & Flockhart, D. A. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-126 · Cited by 277
genotype status and effect of omeprazole on intragastric pH in humans
FURUTA, T., OHASHI, K., KOSUGE, K., ZHAO, X., TAKASHIMA, M., KIMURA, M., NISHIMOTO, M., HANAI, H., KANEKO, E., & ISHIZAKI, T. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70075-5 · Cited by 272
Lim, H.-S., Ju Lee, H., Seok Lee, K., Sook Lee, E., Jang, I.-J., & Ro, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.4850 · Cited by 268
Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies
Furuta, T., Shirai, N., Sugimoto, M., Nakamura, A., Hishida, A., & Ishizaki, T. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.153 · Cited by 257
L??tsch, J., Skarke, C., Liefhold, J., & Geisslinger, G. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443140-00003 · Cited by 256
Furuta, T. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113959 · Cited by 254
Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics
JOHNSON, A., WANG, D., & SADEE, W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.001 · Cited by 97
Takahashi, M., Takita, Y., Yamazaki, K., Hayashi, T., Ichikawa, H., Kambayashi, Y., Koeda, T., Oki, J., Saito, K., Takeshita, K., et al. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0154 · Cited by 36
“These individuals possess two nonfunctional alleles and are classified as poor meta-bolizers (PM) (Nakamura et al. 1985; Horai et al. 1990; Broly et al. 1991).”
Metadata
- Authors
- Nakamura, K., Goto, F., Ray, W. A., McAllister, C. B., Jacqz, E., Wilkinson, G. R., & Branch, R. A.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1985-10
- Volume
- 38
- Issue
- 4
- Pages
- 402-408
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1979392961
- Cited by
- 452
- References
- 0
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.